Anaplastic lymphoma kinase (ALK) is a potent oncogenic driver in lung cancer. ALK tyrosine
kinase inhibitors yield significant benefit in patients with ALK fusion-positive (ALK+) lung …

Lung cancer still contributes to nearly one‐quarter cancer‐related deaths in the past
decades, despite the rapid development of targeted therapy and immunotherapy in non …

Details on diagnostic procedures are covered in the Supplementary Material Section 2,
available at https://doi. org/10.1016/j. annonc. 2022.12. 009. See Supplementary Figure S1 …

Circulating tumour DNA (ctDNA) assays conducted on plasma are rapidly developing a
strong evidence base for use in patients with cancer. The European Society for Medical …

Background After a median follow-up of 18· 3 months, the third-generation anaplastic
lymphoma kinase (ALK) tyrosine-kinase inhibitor, lorlatinib, improved progression-free …

Anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC) is
treated with ALK tyrosine kinase inhibitors (TKIs), but the lack of activity of immune …

Eukaryotic cells engage in autophagy, an internal process of self-degradation through
lysosomes. Autophagy can be classified as selective or non-selective depending on the way …

Biomarkers are vital in healthcare as they provide valuable insights into disease diagnosis,
prognosis, treatment response, and personalized medicine. They serve as objective …

Background The APPLE trial aimed to evaluate the feasibility of longitudinal plasma
epidermal growth factor receptor (EGFR) T790M monitoring for the best sequencing strategy …

Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is currently the
standard first-line therapy for EGFR-mutated advanced non-small cell lung cancer (NSCLC) …